Monitoring minimal residual disease in acute myeloid leukemia: ready for prime time?

No abstract is available for this paper.

• Publication year

  2012

• Venue

  The Journal of the National Comprehensive Cancer Network

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.6004/JNCCN.2012.0105PMID 22878826
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high‐dose cytarabine and idarubicin

  2012cited by this paper
• Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation.

  2011cited by this paper
• Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group.

  2011cited by this paper
• Single-Agent Dasatinib Does Not Prevent Hematological Relapse in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) in First Complete Remission, but Persistent or Re-Appearing Molecular Minimal Residual Disease–Results of the DASA-CBF Trial From the French AML Intergroup

  2011cited by this paper
• Independent prognostic variables in acute myeloid leukaemia.

  2011cited by this paper
• Monitoring of minimal residual disease in acute myeloid leukemia

  2011cited by this paper
• Monitoring of minimal residual disease in acute myeloid leukemia: methods and best applications.

  2011cited by this paper
• Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

  2011cited by this paper
• Minimal residual disease in acute lymphoblastic leukemia.

  2010cited by this paper
• Assessment of minimal residual disease in acute myeloid leukemia

  2010cited by this paper
• IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

  2010cited by this paper
• The role of multiparameter flow cytometry for disease monitoring in AML.

  2010cited by this paper
• Prognostic impact of minimal residual disease in CBFB-MYH11-positive acute myeloid leukemia.

  2010cited by this paper
• Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

  2010cited by this paper
• Monitoring minimal residual disease in acute myeloid leukaemia with NPM1 mutations by quantitative PCR: clonal evolution is a limiting factor

  2009cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Monitoring of minimal residual disease in acute myeloid leukemia

  2009cited by this paper
• Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

  2009cited by this paper
• Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy.

  2009cited by this paper
• Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study.

  2009cited by this paper
• Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML.

  2009cited by this paper
• Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy

  2008cited by this paper
• Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

  2008cited by this paper
• Development of minimal residual disease-directed therapy in acute myeloid leukemia.

  2008cited by this paper
• Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study.

  2007cited by this paper
• Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.

  2006cited by this paper
• High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia.

  2006cited by this paper
• Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia

  2006cited by this paper
• The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia

  2006cited by this paper
• The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia.

  2006cited by this paper
• Prognostic index for adult patients with acute myeloid leukemia in first relapse.

  2005cited by this paper
• Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype.

  2005cited by this paper
• Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21)

  2005cited by this paper
• Stability of leukemia‐associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: Comparison with cytomorphologic, cytogenetic, and molecular genetic findings

  2004cited by this paper
• Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia.

  2004cited by this paper
• Quantitative real-time RT-PCR analysis of PML-RAR alpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129.

  2003cited by this paper
• Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.

  2003cited by this paper
• New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts.

  2003cited by this paper
• Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation

  2003cited by this paper
• Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia.

  2003cited by this paper
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  2002cited by this paper
• Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse.

  2002cited by this paper
• Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors.

  2002cited by this paper
• Real-time quantitation of minimal residual disease in inv(16)-positive acute myeloid leukemia may indicate risk for clinical relapse and may identify patients in a curable state.

  2002cited by this paper
• Articles on similar topics can be found in the following Blood collections

  2002cited by this paper
• Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts

  2002cited by this paper
• Analysis of FLT 3 length mutations in 1003 patients with acute myeloid leukemia : correlation to cytogenetics , FAB subtype , and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

  2002cited by this paper
• Immunological evaluation of minimal residual disease (MRD) in acute myeloid leukaemia (AML).

  2002cited by this paper
• Clinical implications of PRAME gene expression in childhood acute myeloid leukemia.

  2002cited by this paper
• Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification.

  2001cited by this paper
• High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).

  2001cited by this paper
• Quantification of CBFbeta/MYH11 fusion transcript by real time RT-PCR in patients with INV(16) acute myeloid leukemia.

  2001cited by this paper
• Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance.

  2001cited by this paper
• Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

  2000cited by this paper
• Therapy of molecular relapse in acute promyelocytic leukemia.

  1999cited by this paper
• A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group.

  1999cited by this paper
• Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial.

  1998cited by this paper
• Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.

  1997cited by this paper
• Long-term follow-up of minimal residual disease in leukemia patients by monitoring WT1 (Wilms tumor gene) expression levels.

  1996cited by this paper
• Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease.

  1996cited by this paper

• Persistent BCR::ABL1 p190 Minimal Residual Disease and Declining Donor Chimerism Following Haploidentical Bone Marrow Transplant in Pediatric Acute Myeloid Leukemia With Dual High-Risk Fusions

  2025cites this paper
• Optimizing Transplant Approaches and Post-Transplant Strategies for Patients With Acute Myeloid Leukemia

  2021cites this paper
• Utility of Immunophenotypic Measurable Residual Disease in Adult Acute Myeloid Leukemia—Real-World Context

  2019cites this paper
• Time to repeal and replace response criteria for acute myeloid leukemia?

  2018cites this paper
• Current status and trends in the diagnostics of AML and MDS.

  2018cites this paper
• Acute myeloid leukaemia.

  2018cites this paper
• Evaluating measurable residual disease in acute myeloid leukemia.

  2018cites this paper
• Is it time to routinely incorporate MRD into practice?

  2018cites this paper
• Effect of processing time on analysis of rare event in minimal residual disease study

  2017cites this paper
• Measurable residual disease testing in acute myeloid leukaemia

  2017cites this paper
• The Prognostic Significance of Measurable (“Minimal”) Residual Disease in Acute Myeloid Leukemia

  2017cites this paper
• Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia

  2017cites this paper
• Acute myeloid leukemia—Major progress over four decades and glimpses into the future

  2016cites this paper
• Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

  2016cites this paper
• Evolving Therapies in Acute Myeloid Leukemia: Progress at Last?

  2016cites this paper
• Incorporating measurable (‘minimal’) residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia

  2016cites this paper
• Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML

  2016cites this paper
• Acute Myeloid Leukemia: Past, Present, and Prospects for the Future.

  2016cites this paper
• Minimal residual disease-directed therapy in acute myeloid leukemia.

  2015cites this paper
• The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

  2015cites this paper
• Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission: Are We Closer to Knowing Who Needs It?

  2014cites this paper
• Recent advancements of flow cytometry: new applications in hematology and oncology

  2014cites this paper
• Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse

  2014cites this paper
• Technical issues: flow cytometry and rare event analysis

  2013cites this paper
• Comparison of Minimal Residual Disease as Outcome Predictor for AML Patients in First Complete Remission Undergoing Myeloablative or Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation

  2013cites this paper
• Evidence-based Focused Review Minimal Residual Disease–directed Therapy in Acute Myeloid Leukemia Literature Search Strategy). Recommendations Were Developed Based on the Grading of Recommendations Assessment Development and Evalu- Ation System (table 1). Search Results and Discussion

  year unknowncites this paper